Phase II Study of LY3023414 in Patients with Advanced Endometrial Cancer Harboring Activating Mutations in the PI3K Pathway

BACKGROUND: PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. METHODS: We conducted a single-arm phase II study of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer
Glavni autori: Rubinstein, Maria M., Hyman, David M., Caird, Imogen, Won, Helen, Soldan, Krysten, Seier, Kenneth, Iasonos, Alexia, Tew, William P., O’Cearbhaill, Roisin E., Grisham, Rachel N., Hensley, Martee L., Troso-Sandoval, Tiffany, Sabbatini, Paul, Guillen, Joyce, Selcuklu, S. Duygu, Zimel, Catherine, Torrisi, Jean, Aghajanian, Carol, Makker, Vicky
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444087/
https://ncbi.nlm.nih.gov/pubmed/31880826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32677
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items